Amylyx Pharmaceuticals Statistics
Total Valuation
AMLX has a market cap or net worth of $1.56 billion. The enterprise value is $1.29 billion.
Important Dates
The last earnings date was Thursday, May 7, 2026, before market open.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AMLX has 111.19 million shares outstanding. The number of shares has increased by 38.81% in one year.
| Current Share Class | 111.19M |
| Shares Outstanding | 111.19M |
| Shares Change (YoY) | +38.81% |
| Shares Change (QoQ) | +0.66% |
| Owned by Insiders (%) | 6.73% |
| Owned by Institutions (%) | 86.61% |
| Float | 83.53M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 5.72 |
| P/TBV Ratio | 5.73 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 17.85, with a Debt / Equity ratio of 0.02.
| Current Ratio | 17.85 |
| Quick Ratio | 17.53 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -63.26% and return on invested capital (ROIC) is -41.34%.
| Return on Equity (ROE) | -63.26% |
| Return on Assets (ROA) | -38.79% |
| Return on Invested Capital (ROIC) | -41.34% |
| Return on Capital Employed (ROCE) | -57.37% |
| Weighted Average Cost of Capital (WACC) | 3.67% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.10M |
| Employee Count | 136 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, AMLX has paid $46,000 in taxes.
| Income Tax | 46,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +164.97% in the last 52 weeks. The beta is -0.10, so AMLX's price volatility has been lower than the market average.
| Beta (5Y) | -0.10 |
| 52-Week Price Change | +164.97% |
| 50-Day Moving Average | 15.23 |
| 200-Day Moving Average | 13.62 |
| Relative Strength Index (RSI) | 44.07 |
| Average Volume (20 Days) | 1,127,259 |
Short Selling Information
The latest short interest is 14.80 million, so 13.31% of the outstanding shares have been sold short.
| Short Interest | 14.80M |
| Short Previous Month | 14.83M |
| Short % of Shares Out | 13.31% |
| Short % of Float | 17.72% |
| Short Ratio (days to cover) | 13.06 |
Income Statement
| Revenue | n/a |
| Gross Profit | -95.90M |
| Operating Income | -159.27M |
| Pretax Income | -150.07M |
| Net Income | -150.11M |
| EBITDA | -158.80M |
| EBIT | -159.27M |
| Earnings Per Share (EPS) | -$1.49 |
Full Income StatementBalance Sheet
The company has $279.77 million in cash and $5.63 million in debt, with a net cash position of $274.14 million or $2.47 per share.
| Cash & Cash Equivalents | 279.77M |
| Total Debt | 5.63M |
| Net Cash | 274.14M |
| Net Cash Per Share | $2.47 |
| Equity (Book Value) | 273.16M |
| Book Value Per Share | 2.46 |
| Working Capital | 269.06M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$120.40 million and capital expenditures -$127,000, giving a free cash flow of -$120.53 million.
| Operating Cash Flow | -120.40M |
| Capital Expenditures | -127,000 |
| Depreciation & Amortization | 467,000 |
| Net Borrowing | 190.74M |
| Free Cash Flow | -120.53M |
| FCF Per Share | -$1.08 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AMLX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -38.81% |
| Shareholder Yield | -38.81% |
| Earnings Yield | -9.60% |
| FCF Yield | -7.70% |
Analyst Forecast
The average price target for AMLX is $23.40, which is 66.31% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $23.40 |
| Price Target Difference | 66.31% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
